06 March 2009
Issue of Equity and Director Share Purchases
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce the issue of 5,000,000 new ordinary shares of 0.2 pence each in the Company ("Ordinary Shares") to institutional and other investors at a price of 20 pence per share to raise gross proceeds of £1 million. All of Futura's Executive Directors have subscribed for shares in this fundraising, in which Canaccord Adams Limited ("Canaccord") acted as broker.
The net proceeds of the fundraising will be used for general corporate and research and development purposes.
The Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to AIM and it is anticipated that trading of the Ordinary Shares will commence on AIM at 8:00am on 12 March 2009. The Company's total issued shared capital following the admission of the Ordinary Shares will be 62,618,840. The total number of voting rights in Futura Medical plc will be 62,618,840.
The Executive Directors' relative subscription for Ordinary Shares in the fundraising is as follows:
| Director's Name | Previous Beneficial Holding | Ordinary Shares Purchased | Price per Share | Revised Beneficial Holding | Revised Beneficial Holding %¹ |
| William Potter | 81,098 | 50,000 | 20p | 131,098 | 0.2094% |
| James Barder² | 303,712 | 125,000 | 20p | 428,712 | 0.6846% |
| Derek Martin | Nil | 125,000 | 20p | 125,000 | 0.1996% |
| David Davies | 407,572 | 125,000 | 20p | 532,572 | 0.8505% |
¹As a percentage of the enlarged issued share capital following the fundraising
²James Barder also has a non-beneficial interest in 416,500 ordinary shares
James Barder, Futura's Chief Executive, said: "I am delighted to announce this fundraising, which will provide additional working capital ahead of our anticipated transformation into a revenue generating and cash generative company through the launch by SSL International plc of our innovative condom, CSD500. My fellow Executive Directors and I are very pleased to have participated in this fundraising, which will allow us to support the development of our exciting product pipeline."
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Tel: +44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com
Nominated Adviser:
Nomura Code Securities Limited
Phil Walker / Giles Balleny
Tel: +44 (0) 20 7776 1200
For media enquiries please contact:
Buchanan Communications Limited
Mark Court / Stasa Filiplic / George Prassas
Tel: +44 (0) 20 7466 5000